Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 1

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 1
---
 the accompanying proxy statement for the Annual Meeting (the “proxy statement”). Other than the proposals described in the proxy statement, the Company’s board of directors (the “Board”) is not aware of any other matters to be presented for a vote at the Annual Meeting. Your vote is important. Whether or not you plan to virtually attend the Annual Meeting, we encourage you to vote as soon as possible to ensure that your shares are represented. Information about voting methods is set forth in the accompanying proxy statement. Only CERo stockholders of record at the close of business on March 31 , 2025 will be entitled to vote at the Annual Meeting and any adjournment or postponement hereof. On behalf of the Company, thank you for your continued support. Sincerely,

| Chris Ehrlich                                   |
| Chairman, Chief Executive Officer, and Director |

THIS PROXY STATEMENT AND ENCLOSED PROXY CARD ARE
FIRST BEING MADE AVAILABLE ON OR ABOUT , 2025.

CERO THERAPEUTICS HOLDINGS, INC. 201 Haskins Way, Suite 230
South San Francisco, CA 94080 NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON , 2025 Dear Stockholders: NOTICE IS HEREBY GIVENthat the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of CERo Therapeutics Holdings, Inc. (the “Company” or “CERo”) will be held on, 2025, atPacific Time. The Annual Meeting will be held in a virtual meeting format only. We are holding the meeting for the purpose of considering and acting upon: 1.The approval of an amendment to our Second Amended and Restated Certificate of Incorporation, as amended (“Certificate of Incorporation”) to combine outstanding shares of our common stock, par value $0.0001 per share (“Common Stock”), into a lesser number of outstanding shares (the “Reverse Stock Split”), by a ratio of not less than one -for-and not more than one -for-, with the exact ratio to be set within this range by our board of directors (the “Board”) in its sole discretion (the “Reverse Stock Split Proposal” or “Proposal No. 1”); 2.The approval, subject to certain conditions, of the issuance of shares of Common Stock in accordance with Nasdaq Listing Rule 5635 upon the exercise of warrants to purchase Common Stock (the “February 2025 Common